Liora Segal1, Liora S Katz, Monica Lupu-Meiri, Hagit Shapira, Judith Sandbank, Marvin C Gershengorn, Yoram Oron. 1. From the *Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel; †Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; ‡Institute of Pathology, Central Lab, Maccabi, Rehovot, Israel; and §Assaf Harofe Hospital Institute of Pathology and the Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Abstract
OBJECTIVES: Proteinase-activated receptor-1 (PAR-1) and PAR-2 have been associated with increased invasiveness and metastasis in human malignancies. The role of PAR-3 has been less investigated. We examined the role of PARs in a human pancreatic adenocarcinoma PANC-1 cell line phenotype in vitro. METHODS: We knocked down PAR-1, PAR-2, or PAR-3, whereas empty vector-infected cells served as controls. Specific peptide agonists of PARs were used to stimulate the receptors. In vitro assays of colony formation, migration, and invasion were used to characterize the phenotypes, and Western analysis was used to follow cell division control protein 42 homolog (CDC42) expression. RESULTS: PAR-1 and PAR-2 knockdowns (KDs) were markedly less, whereas PAR-3 KDs were robustly more migratory and invasive than the controls. Stimulation of PAR-1 or PAR-2 by their peptide agonists increased, whereas PAR-3 agonist reduced the invasion of the control cells. Knockdowns of all three PARs exhibited changes in the expression of CDC42, which correlated with the changes in their invasion. Conversely, stimulation of vector-control cells with PAR-1 or PAR-2 agonists enhanced, whereas PAR-3 agonist reduced the expression of CDC42. In the respective KD cells, the effects of the agonists were abrogated. CONCLUSION: The expression and/or activation of PARs is linked to the invasiveness of PANC-1 cells in vitro, probably via modulation of the expression of CDC42.
OBJECTIVES:Proteinase-activated receptor-1 (PAR-1) and PAR-2 have been associated with increased invasiveness and metastasis in humanmalignancies. The role of PAR-3 has been less investigated. We examined the role of PARs in a humanpancreatic adenocarcinomaPANC-1 cell line phenotype in vitro. METHODS: We knocked down PAR-1, PAR-2, or PAR-3, whereas empty vector-infected cells served as controls. Specific peptide agonists of PARs were used to stimulate the receptors. In vitro assays of colony formation, migration, and invasion were used to characterize the phenotypes, and Western analysis was used to follow cell division control protein 42 homolog (CDC42) expression. RESULTS:PAR-1 and PAR-2 knockdowns (KDs) were markedly less, whereas PAR-3 KDs were robustly more migratory and invasive than the controls. Stimulation of PAR-1 or PAR-2 by their peptide agonists increased, whereas PAR-3 agonist reduced the invasion of the control cells. Knockdowns of all three PARs exhibited changes in the expression of CDC42, which correlated with the changes in their invasion. Conversely, stimulation of vector-control cells with PAR-1 or PAR-2 agonists enhanced, whereas PAR-3 agonist reduced the expression of CDC42. In the respective KD cells, the effects of the agonists were abrogated. CONCLUSION: The expression and/or activation of PARs is linked to the invasiveness of PANC-1 cells in vitro, probably via modulation of the expression of CDC42.
Authors: Teresa Gómez Del Pulgar; Fátima Valdés-Mora; Eva Bandrés; Rosa Pérez-Palacios; Carolina Espina; Paloma Cejas; Miguel Angel García-Cabezas; Manuel Nistal; Enrique Casado; Manuel González-Barón; Jesús García-Foncillas; Juan Carlos Lacal Journal: Int J Oncol Date: 2008-07 Impact factor: 5.650
Authors: Daniel S Lupu; Luz D Orozco; Ying Wang; John M Cullen; Matteo Pellegrini; Steven H Zeisel Journal: FASEB J Date: 2017-02-08 Impact factor: 5.191
Authors: David Witte; Franziska Zeeh; Thomas Gädeken; Frank Gieseler; Bernhard H Rauch; Utz Settmacher; Roland Kaufmann; Hendrik Lehnert; Hendrik Ungefroren Journal: J Clin Med Date: 2016-11-30 Impact factor: 4.241
Authors: Hendrik Ungefroren; David Witte; Bernhard H Rauch; Utz Settmacher; Hendrik Lehnert; Frank Gieseler; Roland Kaufmann Journal: Int J Mol Sci Date: 2017-11-22 Impact factor: 5.923
Authors: Hendrik Ungefroren; Frank Gieseler; Roland Kaufmann; Utz Settmacher; Hendrik Lehnert; Bernhard H Rauch Journal: Int J Mol Sci Date: 2018-05-24 Impact factor: 5.923